| Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. New Engl J Med 327:1478-1484, 1992. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, Cabanillas F, Canellos GP, Coiffier B, Connors JM, Cowan RA, Crowther D, Dahlberg S, Engelhard M, Fisher RI, Gisselbrecht C, Horning SJ, Lepage E, Lister TA, Meerwaldt JH, Montserrat E, Nissen NI, Oken MM, Peterson BA, Tondini C, Velasquez WS, Yeap BY: A predictive model for aggressive lymphoma: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993. Bloomfield CD, Shuma C,Regal L, Philip PP, Hossfeld DK, Hagemeijer AM, Garson OM, Peterson BA, Sakurai M, Alimena G, Berger R, Rowley JD, Ruutu T, Mitelman F, Dewald GW, Swansbury J: Long-term survival of patients with acute myeloid leukemia. A third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 80:2191-2198, 1997. Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM: MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival : The 8-year results of the intergroup trial. J Clin Oncol 16:19-26, 1998. Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Canellos GP, Johnson JL, Peterson BA: Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B Studies 8852 and 8854. Cancer 92:207-217, 2001. Lee EJ, Petroni GR, Freter CR, Johnson JL, Barcos M, Frizzera G, Bloomfield CD, Schiffer CA, Peterson BA: Brief duration high intensity chemotherapy for patients with small noncleaved cell lymphoma or FAB L3 acute lymphocytic leukemia. Results of Cancer and Leukemia Group B study 9251. J Clin Oncol 19:4014-4022, 2001. Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI: Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol, 19:4238-4244, 2001. Peterson BA, Petroni GR, Frizzera G, Barcos M, Bloomfield CD, Nissen NI, Hurd DD, Henderson ES, Sartiano GP, Johnson JL, Holland JF, Gottlieb AJ: Prolonged single-agent versus combination chemotherapy in indolent follicular, low grade lymphomas. A study of the Cancer and Leukemia Group B. J Clin Oncol 21:5-15, 2003. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21:607-614, 2003.
Rohatiner AZS, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, Fisher RI, Unterhalt M, Arranz R, Chisesi T, Aviles A, Lister TA: Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23:2215-2223, 2005. Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA: Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 104:1661-1667, 2005. Habermann TM, Weller EA, Morrison VA, Cassileth PA, Cohn JB, Dakhil SR, Gascoyne RD, Woda B, Fisher RI, Peterson BA, Horning SJ: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006.
Peterson BA, Johnson J, Shipp MA, Barcos M, Gockerman JP, Canellos GP: High dose CHOP. A phase II study of initial treatment in aggressive non-Hodgkin lymphoma: Cancer and Leukemia Group B 9351. Leuk Lymph 48:870-880, 2007. Smith SM, Johnson J, Cheson BD, Canellos G, Petroni G, Oken M, Duggan D, Hurd D, Gockerman JP, Parker B, Prchl J, Peterson BA. Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naïve follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma 50:1606-1617, 2009. Advani RH, Chen H, Habermann TM, Morrison VA, Weller EA, Fisher RI, Peterson BA, Gascoyne RD, Horning SJ. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol. 151:143-151, 2010. Furman RR, Grossbard, ML, Johnson JL, Pecora AL, Cassileth PA, Petroni GR, Peterson BA, Nadler LM, Hurd DD, Cheson BD. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplantation: CALGB 9254. Leuk Lymphoma. January 28, 2011. (epub ahead of print) Blaes AH, Peterson BA: Hodgkin lymphoma, The Chemotherapy Source Book, Fifth Edition, MC Perry, editor, Wolters Kluwer Heath – Lippincott, Williams & Wilkins, Philadelphia, PA (in press 2011). Wudhikarn K, Holman CJ, Linan M, Blaes AH, Dunitz JM, Hertz ME, Peterson BA. Post-transplant lymphoproliferative disorders in lung transplant recipients: 20 year experience at the University of Minnesota. Clin Transplant 25(5):705-13, 2011. |
